IC
CRNX icon

Ikarian Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ikarian Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-130,902
Closed -$5.83M – 194
2025
Q3 		$5.45M Sell
130,902
-302,529
-70% -$9.67M 0.55% 41
2025
Q2 		$12.5M Sell
433,431
-90,000
-17% -$2.78M 2.39% 11
2025
Q1 		$17.6M Buy
523,431
+7,000
+1% +$261K 2.16% 6
2024
Q4 		$26.4M Buy
516,431
+89,518
+21% +$5.01M 3.59% 5
2024
Q3 		$21.8M Sell
426,913
-161,905
-27% -$8.35M 3.04% 6
2024
Q2 		$26.4M Sell
588,818
-54,933
-9% -$2.54M 4.59% 5
2024
Q1 		$30.1M Sell
643,751
-36,619
-5% -$1.43M 3.3% 3
2023
Q4 		$24.2M Sell
680,370
-112,550
-14% -$3.45M 2.27% 10
2023
Q3 		$23.6M Buy
792,920
+317,920
+67% +$6.55M 2.84% 9
2023
Q2 		$8.56M Buy
+475,000
New +$9.47M 1.36% 23
2020
Q4 		– Sell
-50,000
Closed -$784K – 240
2020
Q3 		$784K Buy
+50,000
New +$764K 0.06% 133

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ikarian Capital's CRNX Position: Q4 2025 in Review

Ikarian Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 130,902 shares — an estimated $5.83M sold.

Ikarian Capital first reported a position in CRNX in Q3 2020 and held it in 11 quarters. The position peaked at $30.1M in Q1 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Ikarian Capital reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 130,902 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $5.83M.
  • Ikarian Capital first reported a position in Crinetics Pharmaceuticals in Q3 2020 and held it in 11 quarters.
  • Ikarian Capital's Crinetics Pharmaceuticals position peaked at $30.1M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.